Epigenetic based synthetic lethal strategies in human cancers
Abstract Over the past decades, it is recognized that loss of DNA damage repair (DDR) pathways is an early and frequent event in tumorigenesis, occurring in 40-50% of many cancer types. The basis of synthetic lethality in cancer therapy is DDR deficient cancers dependent on backup DNA repair pathway...
Saved in:
Main Authors: | Aiai Gao (Author), Mingzhou Guo (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Epigenetic heterogeneity in cancer
by: Mingzhou Guo, et al.
Published: (2019) -
Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy
by: Kailin Li, et al.
Published: (2021) -
The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
by: Victor M. Matias-Barrios, et al.
Published: (2023) -
MPASL: multi-perspective learning knowledge graph attention network for synthetic lethality prediction in human cancer
by: Ge Zhang, et al.
Published: (2024) -
Humanized yeast genetic interaction mapping predicts synthetic lethal interactions of FBXW7 in breast cancer
by: Morgan W. B. Kirzinger, et al.
Published: (2019)